LEAP2 has been reported to be a promising therapeutic target for obesity and other metabolic diseases, with the view that further increasing the LEAP2–ghrelin molar ratio may help restrict food intake [14,84]. The gene discussed is LEAP2; the disease is Other metabolic disease.